This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with pr…

Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8

~Estimated

~$10 – $6,250

University of Michigan Rogel Cancer CenterNCT06616155

Phase 2

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)

This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic cast…

Prostate AdenocarcinomaMetastatic Prostate AdenocarcinomaCastration-resistant

~Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04704505

Observational

Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer

This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivo…

Cancer SurvivorObesityOverweight+17 more

~Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT03880422

← PreviousPage 6 of 6Next →